Evidence map›Paper›PMID 42274212›Full record

ArticleJournal of virology2026

A neutralizing nanobody targeting a conserved lateral patch on HA1 confers protection against multiple H7 avian influenza viruses.

Siqi Xu, Qinying Zhang, Xueer Xie, Mengruo Zhou, Yunxia Chen, Yutong Liu, Chenying Luo, Qi Zhang, Han Zheng, Saixiang Feng and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Siqi XuCollege of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Qinying ZhangCollege of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Xueer XieCollege of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Mengruo ZhouCollege of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Yunxia ChenCollege of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Yutong LiuCollege of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Chenying LuoCollege of Life Sciences, South China Agricultural University, Guangzhou, China.
Qi ZhangCollege of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Han ZhengCollege of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Saixiang FengCollege of Veterinary Medicine, South China Agricultural University, Guangzhou, China.ORCID 0000-0002-7239-3531
Ming LiaoCollege of Veterinary Medicine, South China Agricultural University, Guangzhou, China.ORCID 0000-0001-8731-4528

Funding

China Agricultural Research System 0000-0001-8731-4528National Key Research and Development Program of China 2022YFD1801001National Key Research and Development Program of China 2022YFD1801003The open competition program of top ten critical priorities of Agricultural Science and Technology Innovation Program for the 14th Five-Year Plan of Guangdong Province 2022SDZG02
6 · The paper itself

Abstract

Human infections with H7 avian influenza viruses (AIVs) have been documented globally, involving multiple subtypes and geographic regions. However, effective therapeutics targeting H7 influenza viruses remain limited. Here, a panel of nanobodies targeting the HA1 domain of hemagglutinin (HA) was identified by yeast two-hybrid (Y2H) screening, and six candidates were subsequently validated to exhibit hemagglutination inhibition (HI) activity. Of these, a subset also displayed virus microneutralization (MN) activity, while all showed binding activity in ELISA assays. Among them, Nb74 exhibited inhibitory activity against four Chinese recombinant vaccine-matched strains (Rv1-Rv4), which were generated based on the HA sequences of the corresponding inactivated vaccine strains H7-Re1 to H7-Re4. The HI-IC

Indexed as

Antibodies, NeutralizingAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza A virusInfluenza in BirdsSingle-Domain AntibodiesAnimalsDogsFemaleHemagglutination Inhibition TestsHumansInfluenza VaccinesMiceMice, Inbred BALB CAntibodies, NeutralizingAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesSingle-Domain Antibodiesavian influenza virusHA1 proteinneutralizing nanobodytherapeuticyeast two-hybrid

Identifiers

PMID42274212
PMCPMC13386974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.